PE-22-28
Spadin Analog PE-22-28
PE-22-28: A Faster Path to Relief
PE-22-28 is a synthetic peptide being researched as a potential antidepressant that works through an entirely different mechanism than the medications most people take today. People are interested in it because early studies in animals show it could lift mood in just 24 hours—compared to the two to four weeks typical antidepressants require.
Here's how it works: Your brain uses a chemical messenger called serotonin to regulate mood, and certain neurons release it throughout your brain. These neurons have special gates called TREK-1 channels that normally keep them quiet and inactive. Think of it like a dimmer switch holding the brightness down. PE-22-28 acts as a blocker—it clamps that dimmer switch in the "on" position. With TREK-1 blocked, your serotonin-releasing neurons become more active and fire more frequently, flooding key mood-controlling areas of your brain with more serotonin.
This is fundamentally different from standard antidepressants like SSRIs, which work by preventing serotonin from being recycled away once it's already released. PE-22-28 instead ramps up the release itself from the start, which explains why it might work so much faster. It's a direct neurological effect rather than waiting weeks for your brain's chemistry to slowly rebalance.
Dosage Information
Typical Dose
Research compound — no established human dosing
Frequency
N/A
Administration
Intranasal in animal studies
Half-Life
~30 minutes
estimatedNotes
Currently preclinical research compound. No human clinical trials completed. Significant interest as a rapid-acting antidepressant candidate.
Why this matters
Short half-life; intranasal delivery in animal studies.
Where does PE-22-28 sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.07
Potential Side Effects
PE-22-28 discussions
Quick Facts
- Administration
- Intranasal in animal studies
- Typical Dose
- Research compound — no established human dosing
- Frequency
- N/A
- References
- 0 curated + 0 from PubMed
- Evidence Score
- 0.1 / 100
Frequently Asked Questions about PE-22-28
What is PE-22-28?
PE-22-28 is a synthetic analog of spadin — a peptide derived from the propeptide of TREK-1 potassium channels — that has demonstrated rapid antidepressant effects in animal models. It is notable for producing antidepressant effects within 24 hours in mouse models compared to the 2-4 week onset required for conventional antidepressants. PE-22-28 represents a novel mechanism for antidepressant action through TREK-1 channel blockade and is an emerging area of peptide psychiatry research.
How does PE-22-28 work?
PE-22-28 works by blocking TREK-1 — a two-pore domain potassium channel expressed in serotonergic neurons of the dorsal raphe nucleus. TREK-1 channel activity normally hyperpolarizes serotonergic neurons reducing their firing rate and serotonin release. By blocking TREK-1 PE-22-28 depolarizes serotonergic neurons increasing their firing rate and serotonin release in projection areas including the hippocampus and prefrontal cortex — brain regions critical for mood regulation. This mechanism is distinct from SSRIs which block serotonin reuptake rather than increasing its release. The rapid onset (24 hours vs 2-4 weeks for SSRIs) is attributed to the immediate neurophysiological effect of increased serotonergic firing compared to the delayed synaptic adaptations required for SSRI efficacy.
What is the recommended dosage for PE-22-28?
The typical dose is Research compound — no established human dosing. N/A. Administration: Intranasal in animal studies. Currently preclinical research compound. No human clinical trials completed. Significant interest as a rapid-acting antidepressant candidate.
What are the side effects of PE-22-28?
No human safety data. Research compound only
Questions reflect common community inquiries. This is not medical advice.